Video

Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys

Biology is complicated. Our scientists work with large amounts of scientific data to better understand the relationship between biological entities.

Many of these pieces form a coherent picture about one segment of the biology in question, but often, scientists are presented with conflicting evidence. There are many gaps in the understanding of biology and many blanks remain to be filled. Understanding and filling these gaps is incredibly important for scientists to be able to select the right targets.  

At Benevolent we use various computational technologies and a range of standard and non-standard design patterns to help drug discoverers explore and select the best targets for validation. The role of our machine learning researchers, engineers and designers is to build this technology that helps our scientists break though this vastness of biological information to develop medicines for the patients that need them most.  

Marek, Lead Product Designer, gives a talk at World Usability Day Silesia 2019 in which explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.

More Posts

You Might Also Like

News
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
Sep 14, 2020
Blog
Building the next generation of leaders with Circl
BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.
Aug 21, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Video
How do we get the next 10 years right? w/ Joanna Shields, CogX
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Blog
Kindness matters: mental health and wellbeing through COVID-19 and beyond
To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.
May 27, 2020